Ainos, Inc. (AIMD)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Chun-Hsien Tsai | Chairman of Board, President & CEO | 112.12k | -- | 1970 |
Mr. Lawrence Kennedy Lin | Executive Vice President of Operations | 144k | -- | 1969 |
Mr. Hsin-Liang Lee | Chief Financial Officer | -- | -- | 1971 |
Mr. Chih-Heng Lu | Director of Corporate Developoment | -- | -- | 1980 |
Ainos, Inc.
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 46
Description
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Corporate Governance
Upcoming Events
August 9, 2024 at 8:00 PM UTC - August 13, 2024 at 8:00 PM UTC
Ainos, Inc. Earnings Date
Recent Events
April 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission